؉ or less frequently natural killer cells; in contrast, monoclonal expansions of CD4 ؉ T-LGL have only been sporadically reported in the literature. In the present article we have explored throughout a period of 56 months the incidence of monoclonal expansions of CD4 ؉ T-LGL in a population of 2.2 million inhabitants and analyzed the immunophenotype and the pattern of cytokine production of clonal CD4 ؉
Large granular lymphocyte (LGL) leukemia is a wellrecognized disorder of clonal mature lymphocytes of undetermined significance that commonly displays an indolent course; occasionally it may behave more aggressively. [1] [2] [3] Two different subgroups have been reported: a T-cell and a natural killer (NK)-cell type. 3, 4 In T-LGL leukemia, clonal cells are reported to display a mature effector T-CD8 ϩ cytotoxic phenotype, CD3 ϩ / CD8 ϩ /CD45RA ϩ /CD28 Ϫ /CD27 Ϫ /CD94 ϩ , 5 with variable expression of CD57. 5, 6 CD8 ϩ T-LGL is associated to a mild to moderate stable lymphocytosis, neutropenia, splenomegaly, and to a less extent, anemia;
1 in addition, it shows a strong association with autoimmune diseases, especially rheumatoid arthritis. 5, 6 The diagnostic category for T-LGL leukemia has been restricted to CD8 ϩ cases and CD4 ϩ T-LGL cases are not usually considered within this disease group. However, recently there have been rare reports of CD4 ϩ T-LGL processes that look like the CD8 ϩ LGL leukemia, but have a different immunophenotype. [7] [8] [9] [10] Typically, the few cases of CD4 ϩ T-LGL reported display monoclonal expansions of TCR␣␤ ϩ / CD4 ϩ T-LGL that co-express the CD56 and CD57 NKassociated antigens (NKa ϩ ) and variable levels of CD8 (CD8 Ϫ/ϩdim ).
A subset of circulating CD4 ϩ T cells expressing NKa ϩ and CD8 has been already recognized for a long time both in mice (NK1.1 ϩ T cells) 11 and in humans (TCR␣␤ ϩ / CD4 ϩ /NKa ϩ T cells). 7, [12] [13] [14] Although CD4 ϩ /CD8 ϩ T cells were initially thought to represent recently produced T lymphocytes, accumulating evidence supports the notion that CD4
ϩ /CD8 ϩ lymphocytes are CD4 ϩ T cells that have acquired the CD8 ␣ chain after being activated, and thereafter maintain the CD4 ϩ /CD8 ϩ phenotype. 15, 16 As murine NK1.1 ϩ T cells, human CD4 ϩ /NKa ϩ /CD8
Ϫ/ϩd cells are now believed to be a specialized subset of TCR␣␤ ϩ T cells with different functional roles, including tumor rejection. [17] [18] [19] In this sense, TCR␣␤ ϩ /CD4 ϩ /NKa ϩ T cells have been found at increased proportions in humans in various pathological conditions, including neoplasias, chronic viral infections, autoimmune disorders, and allografts. 20 -30 Previous reports have suggested that, as in mice NK1.1 ϩ T lymphocytes, 31 human CD4 ϩ / NKa ϩ /CD8 Ϫ/ϩd T cells would express a restricted TCR-V␤ repertoire in different disease conditions in which these cells are expanded. [32] [33] [34] [35] As mentioned above, only a few cases displaying monoclonality have been reported so far. Therefore, information currently available on their incidence and characteristics is very limited.
The aim of the present study is to analyze the incidence and the clinical and laboratory features of monoclonal expansions of TCR␣␤ ϩ /CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL and to explore both the immunophenotype and the pattern of cytokine production of these cells. Our results indicate that in these patients the expanded CD4 ϩ T-LGL are both phenotypically and functionally homogeneous and monoclonal CD4 ϩ T-LGL cases show an indolent course in the absence of cytopenias, arthritis, and symptoms directly attributed to the lymphoproliferative disorder itself; however, they frequently have an associated second neoplasia, that is usually determining the clinical course of the disease.
Materials and Methods

Patients and Samples
From September 1997 to April 2002 (both included), samples from a total of 810 adults with monoclonal expansions of mature lymphocytosis were consecutively diagnosed at the Hematology Laboratory of the University Hospital of Salamanca (Salamanca, Spain). This laboratory acts as the reference laboratory for a region of 2.2 million inhabitants in the central-western part of Spain (Castilla y Leó n).
From the 810 monoclonal lymphoproliferative cases, 17 corresponded to monoclonal expansions of CD4 ϩ / NKa ϩ /CD8 Ϫ/ϩd T-cell LGL. Apart from these consecutively received unselected patients, another 17 monoclonal cases suspected of having an expansion of CD4 ϩ / NKa ϩ /CD8 Ϫ/ϩd T-cell LGL were referred from hospitals outside the Castilla y Leó n region, either to the Laboratory of the University Hospital of Salamanca (n ϭ 5) or to a reference laboratory in Portugal (the Hematology Department of the Santo Antonio Hospital, Porto, Portugal) (n ϭ 12) for clonality studies, and included in this study. Accordingly, a total of 34 patients (14 males, 20 females, with a mean age of 65 Ϯ 11 years; range, 40 to 81 years) with monoclonal proliferations of TCR␣␤ ϩ /CD4 ϩ /NKa ϩ / CD8 Ϫ/ϩdim T cells were included in this study. At the moment of closing this study, median follow-up was of 12 months (range, 1 to 89 months).
In all cases, the studies described below were performed in peripheral blood (PB) samples collected into tubes containing either K3-ethylenediaminetetraacetic acid for immunophenotypic and molecular studies or sodium-heparin for functional analyses of cytokine production.
Immunophenotypic and Cytokine Production Studies
Cell Surface and Cytoplasmic Staining
Cell staining was performed using a whole blood stainand-then-lyse method (FACS lysing solution; Becton/ Dickinson Biosciences, San Jose, CA) and a direct immunofluorescence technique as previously reported in detail. 36 Cytoplasmic staining was performed using the Fix & Perm reagent kit (Caltag Laboratories, San Francisco, CA).
The initial screening was performed with a four-color panel of monoclonal antibodies (mAbs) directed against T-and NK-associated antigens conjugated with fluorescein isothiocyanate, phycoerythrin, phycoerythrin-cyanine 5, or peridin chlorophyll protein and allophycocyanin, which include the CD2/CD7/CD56/CD3, TCR␣␤/ CD5/CD3/TCR␥␦, and CD8/CD28/CD4/CD3 stainings. Once the lineage of the expanded LGL was identified as being TCR␣␤ ϩ /CD4 ϩ , these cells were further characterized using the following four-color panels of mAb: CD2/ CD7/CD4/CD8, CD5/CD7/CD4/CD8, CD38/CD11b/CD4/ CD8, CD57/CD11c/CD4/CD8, CD16/CD56/CD4/CD8, CD122/CD25/CD4/CD8, CD45RA/CD45RO/CD4/CD8, CD62L/CD28/CD4/CD8, CD11a/HLA-DR/CD4/CD8, CD16/NKB1/CD4/CD8, CD158a/CD161/CD4/CD8, CD57/CD8/CD56/CD4, and CD57/cytoplasmic (cyt) granzyme B/CD56/CD4. The source and specificity of each mAb reagent used is shown in Table 1 .
For the analysis of the TCR-V␤ repertoire of CD4 ϩ T lymphocytes an extensive panel of 26 mAbs directed against 20 different TCR-V␤ families was used (Table 1) . These reagents covered 60 Ϯ 4% of the TCR-V␤ repertoire of CD4
ϩ T cells present in the PB of normal age-and sex-matched controls. 37 Diagnosis of a TCR-V␤ expansion was based on previously defined criteria: 37 whenever a given TCR-V␤ family was over-represented within the CD4 ϩ T-cell compartment (ie, it exceeded the mean value ϩ 2 standard deviations of normal individuals); or if a dilution pattern was observed (ie, the fraction of CD4 ϩ T cells that were recognized was less than or equal to 85% of the mean value observed in normal individuals with the same panel of anti-TCR-V␤ mAb).
Functional Analysis of Cytokine Production
In 23 of the 34 patients with monoclonal expansions of
Ϫ/ϩdim T-LGL was analyzed by flow cytometry. Briefly, 500 l of heparinized PB were placed into a tube containing 500 l of RPMI 1640 culture medium (BioWhittaker, Walkersville, MD) supplemented with L-glutamine (2 mmol/L). Cells were cultured for 4 hours at 37°C in a 5% CO 2 and a 95% humidity sterile environment in the presence of phorbol-12 myristate 13-acetate (25 ng/ml), ionomycin (1 g/ml), and brefeldin A (10 g/ml) (stimulated samples) or only brefeldin A (nonstimulated samples). Once this incubation period was completed, each sample was aliquoted in different vials of 100 l and sequentially stained for surface antigens (CD4 and CD8) and intracellular cytokines [interleukin (IL), IL-4, IL-10, IL-13, interferon-␥, tumor necrosis factor (TNF)-␣, and TNF-␤] (Table 1) , as previously described in detail. 36 
Flow Cytometry Data Acquisition and Analysis
Flow cytometry data acquisition for the immunophenotypic and cytokine production studies was systematically performed in dual-laser FACSCalibur flow cytometers (Becton/Dickinson Biosciences), using the Cell QUEST software program (Becton/Dickinson Biosciences). For each staining, information on a minimum of 2 ϫ 10 5 nongated events was acquired and stored as list mode data. For data analysis the Paint-a-Gate PRO software program (Becton/Dickinson Biosciences) was used.
LGL were first identified based on their flow cytometric characteristics-high sideward (SSC) and forward (FSC) light scatter profile, expression of NKa antigens, and negative/low levels of CD8. Once identified, cells fulfilling these criteria were selected (gated cells), their percentage from total lymphocytes was calculated and they were analyzed for the expression of the surface antigens recognized by the mAb referred above. For each antigen analyzed, the 
Molecular Analysis of T-Cell Clonality
Rearrangements of the TCR-V␤ genes were evaluated by conventional Southern blotting. 38, 39 Briefly, mononuclear cells were obtained after fractionation on a Lymphoprep (Nycomed Pharma AS, Oslo, Norway) density gradient, washed twice in phosphate-buffered saline, and cryopreserved. DNA was extracted using the phenol/chloroform method and digested with EcoRI and HindIII restriction enzymes. DNA fragments were separated by 0.8% agarose gel electrophoresis and transferred to nitrocellulose membranes by vacuum blotting, UV fixed, and hybridized with 32 P-labeled probes for the TCR-␤ gene region (C␤, TCRBC, and TCRBJ2; DAKO A/S, Glostrup, Denmark).
Other Laboratory Studies
Serum was tested for the presence of antibodies to cytomegalovirus, human hepatitis B and C, type 1 and 2 herpes simplex, rubella, human T-cell lymphotrophic type I and II, and human immunodeficiency type 1 and 2 viruses. Rheumatoid factor, anti-nuclear antibodies, and serum immunoglobulin levels were also determined using conventional techniques.
Results
Incidence of Monoclonal Expansions of TCR␣␤
T-LGL were detected in 17 of the 810 consecutive unselected individuals who had a monoclonal proliferation of B-, T-, or NK-cell mature lymphocytes (2% of total). Throughout a period of 56 months, this represents an incidence of 3.64 new cases/year for a region of 2.2 million inhabitants (1.65 new cases/1 million inhabitants).
Clinical and Laboratory Features of Individuals with Monoclonal Expansions of TCR␣␤
From the clinical point of view, individuals with monoclonal expansions of CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL showed a relative indolent disease course. At diagnosis, all except six patients (82%) showed normal physical examination. From the six patients displaying an altered physical examination, three presented organomegalies that were attributed to a concomitant B-cell neoplasia and one patient displayed skin lesions compatible with disseminated granuloma annulare based on clinical and histological findings. The other two patients showed a single small (Ͻ1 cm) adenopathy each; in these two patients, as well as in the remaining cases, diagnosis was made in a routine blood cell analysis (87%). In Table 2 the most relevant clinical and laboratory features of these patients at presentation, are summarized. Interestingly, co-existence of a second neoplasia was found in 10 patients (29%). In six cases these tumors corresponded to hematological disorders, in another three patients to solid tumors, and in the remaining case, a hematological and a solid malignancy co-existed. As shown in Table 3 , the hematological disorders corresponded to a splenic marginal zone B-cell non-Hodgkin's lymphoma (SMZL) (n ϭ 2), a B-cell chronic lymphocytic leukemia (B-CLL) (n ϭ 2), a lymphoplasmacytic lymphoma (LPL) (n ϭ 1) and a leukemia of TCRgd ϩ T-LGL coexisting with a monoclonal gammopathy of undetermined significance (MGUS) (n ϭ 1). The nonhematological malignancies were a thyroid carcinoma (n ϭ 1), gastric adenocarcinoma (n ϭ 1), and a leiomyosarcoma co-existing with a squamous cell carcinoma (n ϭ 1). In the patient in whom two hematological and nonhematological malignancies co-existed, the diagnoses corresponded to a B-CLL and a colorectal adenocarcinoma, respectively. Diagnosis of the clonal TCR␣␤
Ϫ/ϩdim T-LGL expansion was made either simultaneously (n ϭ 6 cases) or before (n ϭ 2) that of the associated disease; in only two cases the diagnosis of the associated tumor preceded that of the monoclonal expansion of PB T cells (Table 3) . Continuous variables shown as mean Ϯ standard deviation (range). *These cases presented abdominal distention because of splenomegaly, related to a co-existing B-cell neoplasia.
† Diagnosed as disseminated granuloma annulare. ‡ B-CLL co-existing with the T-cell expansion. § Half of these cases had an associated B-cell lymphoproliferative disorder, one of which also presented splenomegaly.
From the hematological point of view, both the relative and absolute PB lymphocyte counts were increased (7.1 Ϯ 4.5 ϫ 10 9 lymphocytes/L, corresponding to 60 Ϯ 17% of all PB leukocytes). Morphologically recognizable
LGLs were observed in all cases and they constantly accounted for more than half of all PB lymphocytes (mean percentage of LGL of: 73.8 Ϯ 12%; range, 53 to 91%). The hemoglobin (144 Ϯ 16 g/L), platelet (214 Ϯ 65 ϫ 10 9 /L), and neutrophil (3.7 Ϯ 3.4 ϫ 10 9 /L) counts were within the normal range in all except three cases. Moreover, in 9 of 34 patients (six males and three females) hemoglobin levels were Ն150 g/L.
Serum lactate dehydrogenase levels were within the normal range in all cases, and ␤2-microglobulin levels were within the normal range in all but one case (3.9 mg/L), corresponding to a patient with an associated B-cell lymphoproliferative disorder. There was no serological evidence for recent or persistent viral infection. Increased IgE serum levels were found in one-third of cases (942 Ϯ 1044 U/L; range, 123 to 2119; normal values Ͻ100 U/L). Rheumatoid factor and anti-nuclear antibodies were negative in all patients and only one patient had an associated joint disease documented as osteoarthritis. 
Immunophenotype of clonal TCR␣␤
ϩ /CD4 ϩ / NKa ϩ /CD8 Ϫ/ϩdim T-LGL TCR␣␤ ϩ /CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL
/CD8
Ϫ T-LGL (ratio between FSC and SSC values of CD4 ϩ T-LGL and CD4 ϩ non-LGL T cells of 1.2 Ϯ 0.1 and 1.3 Ϯ 0.1, respectively) and co-expression of cytoplasmic granzyme B as well as of the CD56 and CD57 NKa antigens; reactivity for CD11b was variable, with both positive (47%) and negative (53%) cases (mean number of CD11b ϩ cells, 52 Ϯ 48%; range, 0 to 100%). Other NKa markers, including CD11c, CD16, CD94, CD158a, CD161, and NKB1 were constantly absent on the clonal T cells.
With regard to T-cell associated antigens, TCR␣␤ ϩ / CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL typically co-expressed low and heterogeneous levels of CD8 (88% of cases), the percentage of CD4 ϩ /CD8 ϩdim T cells ranging from 14% to 100% (mean of 60 Ϯ 36%). Additionally, TCR␣␤ ϩ / CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL showed a bright and homogeneous CD2 expression as compared to the TCR␣␤ ϩ /CD4 ϩ /NKa Ϫ /CD8 Ϫ residual T cells; in a similar way, CD5 was also homogeneously positive in all cases, but its levels were frequently slightly reduced. In turn, reactivity for CD7 was constantly heterogeneous and either dim or nearly absent.
In approximately half of the cases (16 of 34, 47%),
ϩ . In addition, clonal T cells constantly expressed increased and homogeneous levels of CD11a; HLA-DR was usually dimly positive and heterogeneously expressed (Figure 1 ). Other surface markers that have been related to T-cell activation, such as CD25, CD28, CD38, CD62L, and CD122 were constantly absent. 
TCR-V␤ Repertoire of Clonal TCR␣␤
/CD8
Ϫ/ϩdim T-LGL had a major TCR-V␤ expansion, which accounted for 74 Ϯ 21% of the total CD4 ϩ T cells. The magnitude of the TCR-V␤ expansion significantly correlated (P Ͻ 0.05) with the fraction of TCR␣␤
Ϫ/ϩdim T-LGL. In 20 cases (59%) we were able to identify the expanded TCR-V␤ family: TCR-V␤2.1 in 4 cases (12%), TCR-V␤3.1 in 2 (6%), TCR-V␤13.1 in 12 (35%), and TCR-V␤17.1 in 2 cases (6%). In the remaining 13 patients the expanded TCR-V␤ family was not represented in the panel of mAbs used. There was no statistical association between the type of TCR-V␤ family expanded and the presence or absence of an associated neoplasia. Molecular studies confirmed the existence of clonal TCR-␤ chain gene rearrangements in all cases. (Figure 2) . Accordingly, these cells produced large amounts of both interferon-␥ and TNF-␣. Interestingly, in 70% of these cases, a variable proportion of the TCR␣␤ ϩ /CD4 ϩ /NKa ϩ /CD8
Ϫ/ϩdim clonal T-LGL (25 Ϯ 21%, range, 6 to 77%) also produced IL-2. By contrast, under these stimulatory conditions, production of IL-4, IL-10, IL-13, and TNF-␤ could not be detected in any of the cases analyzed.
Follow-Up and Clinical Outcome
At the moment of closing this study, all 34 patients remained alive and in the absence of clinical manifestations directly related to the monoclonal TCR␣␤
Ϫ/ϩdim T-cell expansion. Despite this, changes were observed in five cases. One displayed anemia because of gastrointestinal hemorrhage associated with a gastric adenocarcinoma, whereas the other three cases showed pancytopenia because of either bone marrow infiltration by leiomyosarcoma (n ϭ 1) or to treatment for an associated B-cell lymphoproliferative disorder (n ϭ 2). Interestingly, in the fifth case a spontaneous remission of the CD4 ϩ LGL proliferation occurred 4 years after the initial diagnosis, as assessed by immunophenotypic and TCR-V␤ analysis.
Discussion
Recent studies have shown the presence of increased numbers of TCR␣␤ ϩ /CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL in small groups of individuals, from which around one-third were found to be monoclonal. 8 -10 Because of the low number of cases reported and the design of these studies, analysis of the incidence and the clinical and laboratory features of patients displaying a monoclonal ex- 27, 41 However, to the best of our knowledge, until now no other series has provided enough clinical data to speculate about a preferential association between clonal TCR␣␤ ϩ /CD4 ϩ /NKa ϩ /CD8 Ϫ/ϩdim T-LGL proliferations and other neoplasias. Our results not only provide evidence for this association, but they also show that, in some cases, the associated tumor may clinically develop months, or even years, after the diagnosis of the monoclonal T-cell proliferation. The high frequency of second malignancies would support the relevance of performing a wide cancer survey and a close follow-up of patients with clonal expansions of TCR␣␤ ϩ /CD4 ϩ /NKa ϩ / CD8 Ϫ/ϩdim T-LGL, even when there is no evidence of an associated disease at diagnosis, and PB lymphocyte counts are stable. According to the present data, apart from lymphocytosis, neither clinical manifestations nor abnormal levels of laboratory parameters were found unless the patient had a concomitant disease. Thus, in these individuals the presence of clinical symptoms, an abnormal physical examination or high levels of lactate dehydrogenase and ␤2-microglobulin should be considered as an alert for the possibility of an associated neoplasia.
The exact mechanism that could explain the relationship between the TCR␣␤ [17] [18] [19] In the present study, monoclonal TCR␣␤ 
/CD8
Ϫ/ϩdim T-LGL may proliferate and expand as an effort of the immune system to control tumor growth. This hypothesis is also supported by our findings that these cells actively produce Th1 cytokines, consisting mainly of production of high levels of interferon-␥, which has been considered more effective than Th2 cytokines or priming and supporting or anti-tumor cytotoxic T-cell response, 45 and show a preferential use of specific TCR-V␤ families. In any case, further studies are necessary to demonstrate or rule out such hypotheses.
In conclusion, our results show that a proportion of T-LGL may correspond to monoclonal expansions of cytotoxic/Th1 CD4 ϩ T cells; despite their indolent clinical behavior, clear clinical differences exist between these CD4 ϩ T-LGL and the classical CD8 ϩ T-LGL, especially as regards the absence of neutropenia, anemia, and splenomegaly, and the higher incidence of an associated neoplasia in the former group.
